DNA X Receives Nasdaq Delisting Notice for Equity Non-Compliance
SONM sits 61% above its 52-week low of $2.521.
Summary
DNA X, Inc. has received a Nasdaq delisting notice for failing to meet the exchange's minimum stockholders' equity requirement. This critical development follows an 8-K filing minutes earlier, which also disclosed a new $3.05 million financing. The company intends to request a hearing by May 29, 2026, which will temporarily stay the delisting. This notice adds to existing concerns, including a going concern warning and material weakness in financial reporting disclosed in its April 10-K. A delisting would severely impact the stock's liquidity and investor confidence. The outcome of the company's appeal hearing will be crucial.
At the time of this announcement, SONM was trading at $4.07 on NASDAQ in the Technology sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $2.52 to $38.52. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.